Prime Medicine (PRME) Common Equity (2021 - 2026)

Prime Medicine (PRME) has 6 years of Common Equity data on file, last reported at $76.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 28.27% year-over-year to $76.7 million; the trailing twelve-month figure through Mar 2026 stood at $76.7 million (down 28.27% YoY), and the FY2025 full-year result was $120.9 million, down 21.08% from the prior year.
• Common Equity for Q1 2026 stood at $76.7 million, down from $120.9 million in the prior quarter.
• Across five years, Common Equity topped out at $316.3 million in Q4 2022 and bottomed at -$223.1 million in Q3 2022.
• The 5-year median for Common Equity is $153.1 million (2024), against an average of $111.0 million.
• Peak annual rise in Common Equity reached 302.43% in 2022, while the deepest fall reached 136.29% in 2022.
• A 5-year view of Common Equity shows it stood at $316.3 million in 2022, then sank by 57.92% to $133.1 million in 2023, then climbed by 15.09% to $153.1 million in 2024, then slipped by 21.08% to $120.9 million in 2025, then sank by 36.54% to $76.7 million in 2026.
• The last three Common Equity figures came in at $76.7 million (Q1 2026), $120.9 million (Q4 2025), and $161.8 million (Q3 2025), per Business Quant data.

Peer Comparison